Alpha Or Leukocyte Patents (Class 424/85.7)
  • Patent number: 10793554
    Abstract: The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H- benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone:
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: October 6, 2020
    Assignee: Forma Therapeutics, Inc.
    Inventors: George P. Luke, Stephen Hubbs, Matthew W. Martin, Robert Wenslow, Yawei Shi, Jun Huang
  • Patent number: 10745398
    Abstract: The invention relates to novel compounds of the formula (I) in which R1, R2, R3, A1, V, X and n have the meanings given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: August 18, 2020
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: David Wilcke, Rüdiger Fischer, Dominik Hager, Nina Kausch-Busies, Laura Hoffmeister, Kerstin Ilg, Ulrich Görgens, Daniela Portz, Andreas Turberg
  • Patent number: 10723762
    Abstract: For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a chromatography column containing uCPG as chromatography material. It has been found that this effect is pronounced at a pH value of about 4 to 6 in buffered solutions. With approximately 100 m2 to 150 m2 uCPG surface per g of polypeptide almost 80% to 95% of the high molecular weight compounds are removed with a yield of 80% to 90% of polypeptide.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 28, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
  • Patent number: 10688083
    Abstract: Disclosed herein are methods for use of R-chloroquine or clemizole or combinations of R-chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory? conditions, treating liver cancer or reducing the risk of developing liver cancer in a subject. Uses also include methods of treating non-alcoholic steatohepatitis in a subject.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 23, 2020
    Assignee: Eiger Group International, Inc.
    Inventors: Jeffrey S. Glenn, Edward A. Pham
  • Patent number: 10624931
    Abstract: Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 21, 2020
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Alla Danilkovitch, Yi Duan-Arnold, Matthew Moorman, Anne Lerch, Jin-Qiang Kuang
  • Patent number: 10610569
    Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: April 7, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryo Ohori, Kanta Horie
  • Patent number: 10562929
    Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: February 18, 2020
    Assignee: KAYLA THERAPEUTICS
    Inventors: Fabienne Vernejoul, Gerard Tiraby, Thierry Lioux
  • Patent number: 10544199
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: January 28, 2020
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • Patent number: 10537612
    Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: January 21, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryo Ohori, Kanta Horie
  • Patent number: 10519239
    Abstract: Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: December 31, 2019
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
  • Patent number: 10344019
    Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: July 9, 2019
    Assignee: Gilead Pharmasset LLC
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James G. Taylor, Chinh Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila M. Zipfel
  • Patent number: 10337011
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Fibroblast growth factor 21 (FGF21), in particular, by targeting natural antisense polynucleotides of Fibroblast growth factor 21 (FGF21). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of FGF21.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: July 2, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 10329353
    Abstract: The present invention includes the discovery of cell-surface vimentin as a novel biomarker to detect and isolate mesenchymal and epithelial-mesenchymal transformed circulating tumor cells from blood of cancer patients. In addition, an antibody specific for the detection of cell-surface vimentin on circulating tumor cells and the use the antibody to detect, enumerate, and isolate CTC are provided.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: June 25, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Arun Satelli, Shulin Li
  • Patent number: 10280421
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon Regulatory Factor 8 (IRF8), in particular, by targeting natural antisense polynucleotides of Interferon Regulatory Factor 8 (IRF8). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IRF8.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: May 7, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 10238680
    Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 26, 2019
    Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa, Cyril B. Dousson, Gilles Gosselin, Claire Pierra, David Dukhan
  • Patent number: 10233170
    Abstract: The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-? superfamily such as Nodal or Activin.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: March 19, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Donald Payan, Marina Gelman, Todd Kinsella
  • Patent number: 10130612
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: November 20, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Patent number: 10052293
    Abstract: A Curcumin infused milk beverage composition comprising 0.05% to 0.15% alkalized Curcumin, standardized milk with fat, sugar and stabilizing agents, wherein the pH of resultant composition is maintained at 6.8.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 21, 2018
    Inventor: Srikumar Misra
  • Patent number: 9931413
    Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: April 3, 2018
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
  • Patent number: 9907796
    Abstract: Novel compounds and their synthesis are described. Methods for using these compounds in the prevention or treatment of cancer, a bacterial infection or a viral infection in a subject are also described.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: March 6, 2018
    Assignee: INHIBIKASE THERAPEUTICS, INC.
    Inventors: Rhushikesh Chandrabhan Deokar, Sundeep Dugar, Dinesh Mahajan, Milton Henry Werner
  • Patent number: 9775831
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: October 3, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark G. Saulnier, David B. Frennesson, Makonen Belema
  • Patent number: 9669105
    Abstract: Disclosed is a liquid formulation in which a long-acting INF? conjugate that has improved in vivo duration and stability can be stored stably for a long period of time. It comprises a stabilizer comprising a buffer, a sugar alcohol, a non-ionic surfactant and an isotonic agent. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting INF? conjugates.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: June 6, 2017
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Seong Im, Jae Min Lee, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
  • Patent number: 9657302
    Abstract: A plastid transformation vector for a stably transforming a plastid genome is provided. The vector includes, as operably-linked components, a first flanking sequence, a DNA sequence coding for a therapeutic human IFN, which is capable of expression in the plastid and a second flanking sequence. The invention also provides isolated and purified IFN, wherein the IFN is configured in a monomeric or multimeric form and is a structural equivalent to orally administered human IFN. Also provided are methods for variable-expressing biopharmaceutical proteins in plants suitable for mammal consumption. The method includes integrating a plastid transformation vector into a plastid genome of a plant cell; growing the plant cell to express a biopharmaceutical protein, such as therapeutic human interferon IFN. Also disclosed are plants transformed with the aforementioned vectors, and the progeny thereof. Also, disclosed is the IFN, which is IFN?2b.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: May 23, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Henry Daniell
  • Patent number: 9644015
    Abstract: A codon optimized nucleic acid sequence for Interferon Alpha-2a is provided which can be used for expression of Interferon Alpha-2a in E. Coli.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: May 9, 2017
    Assignee: BIOGENOMICS LIMITED
    Inventors: Archana Rajesh Krishnan, Sanjay Madhukar Sonar, Damodar Krishnabahadur Thappa
  • Patent number: 9617547
    Abstract: Problem The purpose of the present invention is to provide: a stereo isomer of a novel CpG oligonucleotide, which has excellent stability; and a CpG oligonucleotide which has a capability of producing interferon-? (IFN?). Solution The present invention relates to an oligonucleotide which contains two to four sequences each represented by the formula 5?-X1X2CpGX3X4-3? (formula (I)) and has a length of 14 to 32 nucleotides. In formula (I), CpG represents a non-methylated CpG residue having a phosphate skeleton modification, X1X2 represents any one of AA, AT, GA and GT, and X3X4 represents any one of TT, AT, AC and CG. The oligonucleotide has at least one phosphate skeleton modification at an S-form stereoisomer located at a site other than the CpG.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: April 11, 2017
    Assignees: Shin Nippon Biomedical Laboratories, Ltd., WAVE LIFE SCIENCES JAPAN
    Inventor: Takefumi Gemba
  • Patent number: 9611479
    Abstract: Disclosed are bridged nucleosides and nucleotides. The nucleosides of the present invention have a 2?,4?-bridged structure and are represented by formula I below: An oligonucleotide containing a 2?,4?-bridged artificial nucleotide of the present invention has a binding affinity for single-stranded RNA comparable to that of known 2?,4?-BNA/LNA and higher nuclease resistance than LNA. In particular, since the oligonucleotide has a much higher binding affinity for single-stranded RNA than S-oligo, it is expected that the oligonucleotide is applicable to nucleic acid drugs.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: April 4, 2017
    Assignee: Osaka University
    Inventors: Satoshi Obika, Takao Yamaguchi, Masahiko Horiba, Reiko Waki
  • Patent number: 9573952
    Abstract: The present invention provides methods of preparing 4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one and related compounds.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: February 21, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Darin Allen, Brandon Heath Brown, Jessica Jade Chao, Randall L. Halcomb, Paul Hrvatin, Ryan McFadden, Paul Roethle, Erwina Rudio, Hong Yang, Richard Hung Chiu Yu
  • Patent number: 9573939
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: February 21, 2017
    Assignees: Merck Sharp & Dohme Corp., MSD Italia SRL
    Inventors: Casey C. McComas, Nigel J. Liverton, Joerg Habermann, Uwe Koch, Frank Narjes, Peng Li, Xuanjia Peng, Richard Soll, Hao Wu, Anandan Palani, Xing Dai, Hong Liu, Shuwen He, Qun Dang
  • Patent number: 9555039
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: January 31, 2017
    Assignee: Forma TM, LLC.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Judith D. Kuntz, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • Patent number: 9534033
    Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: January 3, 2017
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
  • Patent number: 9339541
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: where PD, Base, RA and RB are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: May 17, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Cyril B. Dousson, Benjamin Alexander Mayes, David Dukhan, Adel M. Moussa, Alistair James Stewart
  • Patent number: 9284292
    Abstract: The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but also on protozoa and other micro-organisms, their preparation methods, pharmaceutical formulations containing them and their use as medicinal products for the treatment of various conditions caused by particular microorganisms, including viruses, bacteria and protozoa, which affect animal and human health.
    Type: Grant
    Filed: November 25, 2010
    Date of Patent: March 15, 2016
    Assignee: THERAPICON S.R.L.
    Inventors: Paolo Alberto Veronesi, Pablo E. A. Rodriguez, Anna Maria Veronesi, Emanuela Peschechera
  • Patent number: 9278090
    Abstract: Disclosed is a method of preventing the development of mucositis in a subject undergoing radiation therapy or chemotherapy for a disease in need thereof comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor, such as rapamycin, to the subject. Further disclosed is a method of increasing the lifespan of a normal oral keratinocyte and/or reducing oxidative stress in a normal epithelial cell, wherein the method comprises administering an effective amount of an mTOR inhibitor to a subject undergoing radiation therapy or chemotherapy for a disease in need thereof.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 8, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: J. Silvio Gutkind, Ramiro Iglesias-Bartolome, Vyomesh Patel, Ana p. Cotrim, Alfredo Molinolo, James B. Mitchell
  • Patent number: 9273133
    Abstract: Compositions and methods for treating fibrotic diseases are provided.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: March 1, 2016
    Assignees: Lankenau Institute for Medical Research, Thomas Jefferson University
    Inventors: Allyn Sue Menko, Mindy George-Weinstein, Janice L. Walker, Jacquelyn Gerhart
  • Patent number: 9249174
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: February 2, 2016
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • Patent number: 9243022
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 26, 2016
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • Patent number: 9084806
    Abstract: The present invention relates to an amphiphilic polymer whose property and structure can change under hypoxic conditions, and to nanoparticles formed by self-assembly of the amphiphilic polymer. The hypoxia-responsive nanoparticles according to the present invention release a drug selectively under hypoxic conditions. Thus, the nanoparticles can be used for the selective diagnosis and treatment for diseases that are accompanied by hypoxia. Particularly, the nanoparticles can release a drug only to a targeted tumor in cancer therapy, and thus have minimized side effects and maximized therapeutic effects.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: July 21, 2015
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventor: Jae Hyung Park
  • Patent number: 9072778
    Abstract: The present invention relates to methods and compositions for treating diseases. More specifically, the present invention relates to the administration of multiple drugs as part of a treatment of disease. Specific embodiments of the invention relate to a treatment regimen for neuroblastomas and other N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors, comprising administering multiple therapeutic compounds like DFMO, SAM486A, a verinoid and a cytotoxic drug and placing the patient on a low polyamine diet and/or providing the patient with a polyamine limiting dietary supplement.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: July 7, 2015
    Assignee: UNIVERSITY OF HAWAII
    Inventor: Andre S. Bachmann
  • Publication number: 20150147295
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 28, 2015
    Inventors: Wulf Otto BOECHER, Gerhard NEHMIZ, Wiebke SAUTER, Gerhard G. STEINMANN, Heike ZIMDAHL-GELLING
  • Publication number: 20150139947
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Application
    Filed: October 31, 2014
    Publication date: May 21, 2015
    Applicant: BIOGEN IDEC HEMOPHILIA INC.
    Inventors: ROBERT T. PETERS, ADAM R. MEZO, DANIEL S. RIVERA, ALAN J. BITONI, SUSAN C. LOW
  • Publication number: 20150139951
    Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 21, 2015
    Inventors: Iqbal Grewal, Sanjay Khare, Michael Gresser, Rashid Syed
  • Publication number: 20150139949
    Abstract: The present invention provides methods and compounds for treating viral infections using combinations modulators of an HCV-associated component and modulators of host cell enzymes. The present invention also provides methods and compounds for treating viral infections using combinations of modulators of host cell enzymes and other agents that work, at least in part by modulating hos factors.
    Type: Application
    Filed: May 19, 2014
    Publication date: May 21, 2015
    Inventors: Emre KOYUNCU, Thomas E. SHENK, Joshua RABINOWITZ
  • Publication number: 20150139950
    Abstract: The disclosure concerns the use of cyclophilin inhibitors in the treatment of chronic Hepatitis C virus infection.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 21, 2015
    Applicant: Novartis AG
    Inventor: Claudio Avila
  • Patent number: 9034310
    Abstract: A method for pharmacological treatment of cancers and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: May 19, 2015
    Inventor: Stephen B. Cantrell
  • Publication number: 20150132217
    Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 14, 2015
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi
  • Publication number: 20150132261
    Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Inventors: Martin Joseph Cummins, Chau-Ting Yeh, Ching-Yuan Lee
  • Publication number: 20150132258
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 14, 2015
    Inventor: George D. Hartman
  • Publication number: 20150132260
    Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 14, 2015
    Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
  • Publication number: 20150125423
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 7, 2015
    Inventors: Jennifer Mitcham, Matthew Moyle
  • Publication number: 20150125422
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola